Frankfurt
27.02.26 | 08:09
0,137 Euro
-8,05 % -0,012
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2025 | 264 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available... ► Artikel lesen | |
| Di | AlzeCure Pharma: Pain Project ACD440 Granted Orphan Drug Status in the EU | 780 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 24, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous... ► Artikel lesen | |
| 03.02. | AlzeCure Pharma: AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026 | 724 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 02.02. | AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam | 1.078 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 2, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.12.25 | AlzeCure Pharma: AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease | 371 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system... ► Artikel lesen | |
| 11.11.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2025 | 284 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January... ► Artikel lesen | |
| 14.10.25 | AlzeCure Pharma: Response Letter to Previous Article Published about Alzstatin's Unique Mode of Action Against Alzheimer's | 618 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| 08.09.25 | AlzeCure Pharma: Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025 | 357 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 04.09.25 | AlzeCure Pharma: Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference | 378 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 4, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 26.08.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2025 | 457 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 26, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - June 2025 is now available on the company's... ► Artikel lesen | |
| 20.08.25 | AlzeCure Pharma: AlzeCure Appoints Cecilia Wadell as New Head of Development | 478 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 19.08.25 | AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs | 460 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 19, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 11.08.25 | New last trading day for paid subscription shares (BTA) of AlzeCure Pharma AB | 326 | GlobeNewswire | At the request of AlzeCure Pharma AB, the last trading day in AlzeCure Pharma AB's paid subscription shares will be changed from 2025-08-14 to 2025-08-13.
Instrument:
Paid subscription... ► Artikel lesen | |
| 05.08.25 | AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference | 459 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 29.07.25 | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 576 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 24.07.25 | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option | 428 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 23.07.25 | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed According to Preliminary Results | 377 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 21.07.25 | AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference | 412 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 16.07.25 | AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue | 362 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 15.07.25 | AlzeCure Pharma: AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA | 425 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 420,00 | -0,11 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| VIATRIS | 12,690 | +0,59 % | Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10% | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) reported a fourth quarter net loss of $340.1 million or $0.30 per share compared to a loss of $516.5 million or $0.43 per share, prior year. The company... ► Artikel lesen | |
| ALTIMMUNE | 3,700 | +1,31 % | Forget Altimmune: This Proven Obesity-Drug Giant Is the Better Weight-Loss Play | ||
| OPKO HEALTH | 1,020 | 0,00 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| JAGUAR HEALTH | 0,881 | +7,97 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.02.2026 | Das Instrument UZ9 CA4577022078 INSPIRATION ENERGY CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 27.02.2026 und ex Kapitalmassnahme am 02.03.2026 The instrument UZ9 CA4577022078 INSPIRATION ENERGY... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,140 | -0,96 % | SELLAS LIFE SCIENCES GROUP INC zeigt strukturelle Stärke | ||
| AURINIA PHARMACEUTICALS | 11,820 | -1,46 % | Aurinia targets $305M-$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development | ||
| KIORA PHARMACEUTICALS | 2,110 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference | Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life... ► Artikel lesen | |
| LIPOCINE | 9,930 | -1,19 % | Lipocine Inc.: Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) | SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,600 | +7,22 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results... ► Artikel lesen | |
| PHOTOCURE | 5,120 | -0,58 % | Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe | OSLO, Norway, Feb. 27, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 23,000 | -2,13 % | Eurobio Scientific: 2025 FY revenue | FISCAL YEAR 2025, CONFIRMATION OF STRATEGIC TRANSFORMATION 9% increase in annual revenue to €168 millionDeployment of the Group's strategy: Proprietary products: 35% of revenueInternationalization:... ► Artikel lesen | |
| MEDICURE | 0,775 | +14,81 % | Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025 | WINNIPEG, MB / ACCESS Newswire / November 19, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 42,010 | +0,39 % | Märkte am Morgen: Bayer, SAP, Scout24, Knorr-Bremse, thyssenkrupp, Bitcoin | Der DAX hat eine turbulente Woche hinter sich. Am Freitag gab es noch einmal einen ordentlichen Schub nach oben. In den USA hatte der Supreme Court die Zölle von Donald Trump für unrechtmäßig erklärt.... ► Artikel lesen | |
| NOVO NORDISK | 31,600 | -0,24 % | Opening Bell: Coca-Cola, Nvidia, Eli Lilly, Novo Nordisk, Vistra Energy, Energy Fuels | An der Wall Street richtet sich die Aufmerksamkeit mal wieder auf die Zollpolitik von Donald Trump. Der Supreme Court hatte am Freitag die bisherigen Maßnahmen gekippt. Trump mit neuen Zöllen unter... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,137 Euro und damit -8,05 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.